Design Therapeutics, Inc. Common Stock

DSGNNASDAQ • USD
ThemeBiotech - Drug Development›Rare Disease Therapeutics
10.83 USD
↗ 0.10 (0.97%)🟢PRE MARKET (AS OF 07:27 AM EDT)
🟢Market: OPEN

Design Therapeutics, Inc. Common Stock (DSGN) trades at $10.83 per share. Both sides of the analysis point lower: technicals flash "Sell" and fundamentals confirm with a "Sell" reading. This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On valuation, DSGN trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Oct 21, 2026.

Open?$10.72
High?$13.73
Low?$8.32
Prev. Close?$10.73
Volume?118
Avg. Volume?689.6K
VWAP?$10.76
Rel. Volume?0.00x
Bid / Ask
Bid?$9.27 × 100
Ask?$12.26 × 100
Spread?$2.99
Midpoint?$10.77
Valuation & Ratios
Market Cap?671.5M
Shares Out?N/A
Float?30.5M
Float %?48.7%
P/E Ratio?N/A
P/B Ratio?3.33
EPS?-$1.13
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
Themes
Biotech - Drug Development›Rare Disease TherapeuticsHealthcare - Genomics & Precision Medicine›Gene Therapy & Gene Editing
Employees
55
Market Cap
694.7M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.designtx.com
Listed
2021-03-26
Address
6005 HIDDEN VALLEY ROAD
CARLSBAD, CA 92011
Phone: 858-293-4900
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▲ Bullish(+1/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
15
Piotroski F-Score?0/9Weak
Altman Z-Score?28.08Safe
Confidence?48%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?21.70%Squeeze Risk
Short Interest?6.6M
Days to Cover?8.7
Free Float30.5M
Avg Daily Volume761.0K
Settlement Date2026-09-30
Financial Health
Current Ratio?18.86Strong
Quick Ratio?18.86Strong
Cash Ratio?1.15Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
51
3.33FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-8.4CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
5
-35.1%WEAK▾
ROA?
S&P
3
-32.9%WEAK▾
Cash Flow & Enterprise
FCF?$-55138000
Enterprise Value?$658.6M
Fundamentals ratios updated end of day
MarketsMoversWatchlist